Class information for:
Level 1: CAS 89396 94 1//TA 6366//MOEXIPRIL

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1035 2802 27.2 54%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1986 5072 HEREDITARY ANGIOEDEMA//C1 INHIBITOR//ANGIOEDEMA

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CAS 89396 94 1 Author keyword 18 89% 0% 8
2 TA 6366 Author keyword 18 89% 0% 8
3 MOEXIPRIL Author keyword 14 51% 1% 19
4 IMIDAPRIL Author keyword 11 35% 1% 26
5 FOSINOPRILAT Author keyword 6 58% 0% 7
6 FOSINOPRIL Author keyword 6 20% 1% 27
7 BENAZEPRIL Author keyword 6 18% 1% 28
8 QUINAPRIL Author keyword 5 16% 1% 26
9 CILAZAPRIL Author keyword 4 16% 1% 25
10 SAFETY YODOGAWA KU Address 4 75% 0% 3

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CAS 89396 94 1 18 89% 0% 8 Search CAS+89396+94+1 Search CAS+89396+94+1
2 TA 6366 18 89% 0% 8 Search TA+6366 Search TA+6366
3 MOEXIPRIL 14 51% 1% 19 Search MOEXIPRIL Search MOEXIPRIL
4 IMIDAPRIL 11 35% 1% 26 Search IMIDAPRIL Search IMIDAPRIL
5 FOSINOPRILAT 6 58% 0% 7 Search FOSINOPRILAT Search FOSINOPRILAT
6 FOSINOPRIL 6 20% 1% 27 Search FOSINOPRIL Search FOSINOPRIL
7 BENAZEPRIL 6 18% 1% 28 Search BENAZEPRIL Search BENAZEPRIL
8 QUINAPRIL 5 16% 1% 26 Search QUINAPRIL Search QUINAPRIL
9 CILAZAPRIL 4 16% 1% 25 Search CILAZAPRIL Search CILAZAPRIL
10 TEMOCAPRIL 4 30% 0% 10 Search TEMOCAPRIL Search TEMOCAPRIL

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 HOE 498 15 77% 0% 10
2 MK 421 9 48% 0% 14
3 MK521 6 80% 0% 4
4 CI 906 6 71% 0% 5
5 LISINOPRIL HYDROCHLOROTHIAZIDE COMBINATION 6 100% 0% 4
6 NORMOTENSIVE MAN 5 55% 0% 6
7 NEWER ACE INHIBITORS 4 67% 0% 4
8 LYSINE ANALOG MK 521 4 56% 0% 5
9 MODERATE ESSENTIAL HYPERTENSION 4 14% 1% 26
10 ENALAPRIL MALEATE 4 22% 1% 16

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
CONVERTING-ENZYME INHIBITORS IN THE TREATMENT OF HYPERTENSION 1988 369 70 71%
ENALAPRIL - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN HYPERTENSION AND CONGESTIVE-HEART-FAILURE 1986 277 155 72%
QUINAPRIL - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES, AND THERAPEUTIC EFFICACY IN CARDIOVASCULAR DISORDERS 1991 54 49 86%
CLINICAL PHARMACOKINETICS OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS IN RENAL-FAILURE 1993 48 96 77%
CLINICAL PHARMACOKINETICS OF THE NEWER ACE INHIBITORS - A REVIEW 1990 76 90 88%
CLINICAL PHARMACOKINETICS OF RAMIPRIL 1994 25 26 100%
PERINDOPRIL - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN CARDIOVASCULAR DISORDERS 1991 60 77 70%
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension 2008 21 137 44%
CHOOSING THE RIGHT ACE-INHIBITOR - A GUIDE TO SELECTION 1995 57 127 51%
NEWER ACE INHIBITORS - A LOOK AT THE FUTURE 1990 74 111 76%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 SAFETY YODOGAWA KU 4 75% 0.1% 3
2 CLINCAL PHARMACOL 1 50% 0.0% 1
3 PAD DR DY PATIL MED 1 50% 0.0% 1
4 SANTE ANIM SA 1 50% 0.0% 1
5 WERK ROSENTAL 1 25% 0.1% 2
6 ANGERS TECHNOPOLE 0 33% 0.0% 1
7 HOSP THER Y 2 0 33% 0.0% 1
8 MED EDUC FAMILY MED 0 33% 0.0% 1
9 PHARMACEUT BIOCHEM ENGN 0 33% 0.0% 1
10 SACRED CONVENT ANNUNCIAT 0 33% 0.0% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000222298 TRANDOLAPRIL//MULTI PHOTON CONTAMINATION//VERAPAMIL SR TRANDOLAPRIL COMBINATION THERAPY
2 0.0000167899 ADR MONITORING//BOVINE BRONCHI//ACE I INHIBITOR
3 0.0000149143 UNITE PHYSIOL INTEGREE//ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST//PATHOL VASC
4 0.0000137311 FLOSEQUINAN//BTS 53 554//FIRST DOSE HYPOTENSION
5 0.0000101322 MINICHAL//ANTIHYPERTENSIVE DRUG CLASSES//ANTIHYPERTENSIVE REGIMENS
6 0.0000100643 BLOOD FLOW ACCELERATION//EQUIPMENT AUTOMATIC BLOOD PRESSURE//STRAIN GAUGE VENOUS PLETHYSMOGRAPHY
7 0.0000094213 NONMODULATION//HYPERTENSION NONMODULATING//EXTREME NORTH
8 0.0000087463 CD143//ANGIOTENSIN I CONVERTING ENZYME//TESTICULAR ACE
9 0.0000082875 ADRENAL RENIN//ANGIOTENSINOGEN//TISSUE RENIN
10 0.0000082459 REDUCTIVE RING CLOSURE//THERMAL CYCLISATION//PHENOXYBENZAMINE HYDROCHLORIDE